Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Q1 Revenues up 15 Percent

NEW YORK — Bruker on Thursday reported a 15 percent year-over-year increase in first quarter revenues with gains across all of its business segments.

For the three-month period ended March 31, Bruker's revenues climbed to $685.3 million from $595.0 million the year before. Analysts had, on average, been expecting revenues of about $639.8 million.

Growth from acquisitions was up around 2 percent and offset by a negative effect from foreign currency translation of 4.5 percent.

Bruker's CALID unit, which includes its life sciences and mass spectrometry business, posted a 16 percent jump in revenues for the quarter to $236.7 million from $203.2 million a year earlier. Bruker BioSpin revenues were up 14 percent in the first quarter to $180.3 million from $157.8 million, while Bruker Nano's revenues rose 17 percent to $209.6 million from $178.5 million. Bruker Energy & Supercon Technologies (BEST) revenues edged up 4 percent to $62.2 million from $59.7 million.

Bruker reported a first quarter net profit of $76.5 million, or $.52 per share, compared with a year-ago profit of $61.6 million, or $.41 per share. Non-GAAP earnings per share in Q1 2023 were $.64, topping the consensus Wall Street estimate of $.55 per share.

The Billerica, Massachusetts-based company's R&D costs in the quarter increased 22 percent to $69.0 million from $56.6 million, while SG&A spending rose nearly 12 percent to $162.7 million from $145.7 million.

Bruker ended the quarter with cash, cash equivalents, and restricted cash of $601.4 million.

Looking ahead, Bruker said that it is raising its revenue guidance for full-year 2023 to between $2.83 billion and $2.88 billion compared to a previous outlook of $2.81 billion to $2.86 billion. The raised guidance implies 12 percent to 14 percent year-over-year reported revenue growth including organic revenue growth of 9 percent to 11 percent.

The company now expects non-GAAP earnings for 2023 of between $2.55 and $2.60 per share, up from prior guidance of $2.52 to $2.57 per share.

During early morning trading on the Nasdaq, shares of Bruker were up $3.53 to $83.76.

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.